Current Issue : Oncology Times
Independent and targeted hematology/oncology news for cancer patient care team; breaking clinical news; oncology analysis and commentary; professional trends.
Independent and targeted hematology/oncology news for cancer patient care team; breaking clinical news; oncology analysis and commentary; professional trends.
An abstract is unavailable.
porter 1 inhibitor verinurad combined with the xanthine oxidase inhibitor allopurinol in patients with CKD and hyperuricemia. Methods: In this randomized placebo and active controlled…
and safety after conversion to belatacept. Methods We prospectively enrolled 311 kidney transplant recipients from 2007 to 2020 from two referral centers, converted from CNI…
An abstract is unavailable.
An abstract is unavailable.
atients with CKD. Whether daprodustat affects the risk of heart failure hospitalization is unknown. Methods: The ASCEND-D (n=2,964) and ASCEND-ND (n=3,872) trials compared daprodustat to…
s either cause no effect or a slight reduction in plasma K+ concentration in patients with normal kidney function but seem to exert a protective…
ntify the variability in the ideal entry point (IEP) for MHSs. Methods: Standing alignment radiographs of 50 patients were evaluated using TraumaCad (Brainlab). The femoral…
An abstract is unavailable.
An abstract is unavailable.